Mélanie Prague
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mélanie Prague has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Rodolphe Thiébaut
University of Bordeaux, Inserm Bordeaux Population Health, Inria SISTM, CHU de Bordeaux, Vaccine Research Institute
18 shared publications - Marie Alexandre
Department of Public Health, Bordeaux University, Inserm UMR 1219 Bordeaux Population Health Research Center, Inria SISTM, Bordeaux, France
9 shared publications - Linda Wittkop
Bordeaux Population Health Research Center INSERM U1219, Université de Bordeaux - ISPED, Bordeaux, France; INRIA SISTM, Talence, France; CHU de Bordeaux, Service d'information médicale, INSERM, Bordeaux, France
5 shared publications - Boris Pierre Hejblum
Univ. Bordeaux, INSERM, INRIA, Bordeaux Population Health, SISTM team, U1219, F-33000 Bordeaux, France
4 shared publications Carole Vignals
Inria, Inria Bordeaux – Sud-Ouest, Talence , Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, SISTM Team, UMR 1219 , F-33000 Bordeaux , France
3 shared publications- Jane M. Heffernan
Department of Mathematics and Statistics, York University, Toronto, Ontario, Canada
3 shared publications
Latest Publications
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Utilisation des modèles dynamiques pour l'optimisation des traitements des patients infectés par le VIH
La plupart des patients infectés par le VIH ont une charge virale qui peut être rendue indétectable par des combinaisons antirétrovirales hautement actives (cART); cependant, il existe des effets secondaires aux traitements. L'utilisation des modèles mécanistes dynamiques basés sur des équations différentielles ordinaires (ODE) a considérablement amélioré les connaissances de la dynamique HIV-système immunitaire et permet d'envisager une personnalisation du traitement. L'objectif de ces travaux de thèse est d'améliorer les techniques statistiques d'estimation de paramètres dans les modèles mécanistes dynamiques afin de proposer des stratégies de surveillance et d'optimisation des traitements. Après avoir introduit NIMROD un algorithme d'estimation bayésienne basé sur une maximisation de la vraisemblance pénalisée, nous montrons la puissance des approches mécanistes dynamiques pour l'évaluation des effets traitements par rapport aux méthodes descriptives d'analyse des trajectoires des biomarqueurs. Puis, nous définissons le « modèle à cellules cibles », un système ODE décrivant la dynamique du VIH et des CD4. Nous montrons qu'il possède de bonnes capacités prédictives. Nous proposons une preuve de concept de la possibilité de contrôler individuellement la dose de traitement. Cette stratégie adaptative réajuste la dose du patient en fonction de sa réaction à la dose précédente par une procédure bayésienne. Pour finir, nous introduisons la possibilité de l’'individualisation des changements de cART. Ce travail passe par la quantification in vivo d'effets de cART en utilisant des indicateurs d'activité antivirale in vitro. Nous discutons la validité des résultats et les étapes méthodologiques nécessaires pour l'intégration de ces méthodes dans les pratiques cliniques.
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Utilisation des modèles dynamiques pour l'optimisation des traitements des patients infectés par le VIH
La plupart des patients infectés par le VIH ont une charge virale qui peut être rendue indétectable par des combinaisons antirétrovirales hautement actives (cART); cependant, il existe des effets secondaires aux traitements. L'utilisation des modèles mécanistes dynamiques basés sur des équations différentielles ordinaires (ODE) a considérablement amélioré les connaissances de la dynamique HIV-système immunitaire et permet d'envisager une personnalisation du traitement. L'objectif de ces travaux de thèse est d'améliorer les techniques statistiques d'estimation de paramètres dans les modèles mécanistes dynamiques afin de proposer des stratégies de surveillance et d'optimisation des traitements. Après avoir introduit NIMROD un algorithme d'estimation bayésienne basé sur une maximisation de la vraisemblance pénalisée, nous montrons la puissance des approches mécanistes dynamiques pour l'évaluation des effets traitements par rapport aux méthodes descriptives d'analyse des trajectoires des biomarqueurs. Puis, nous définissons le « modèle à cellules cibles », un système ODE décrivant la dynamique du VIH et des CD4. Nous montrons qu'il possède de bonnes capacités prédictives. Nous proposons une preuve de concept de la possibilité de contrôler individuellement la dose de traitement. Cette stratégie adaptative réajuste la dose du patient en fonction de sa réaction à la dose précédente par une procédure bayésienne. Pour finir, nous introduisons la possibilité de l’'individualisation des changements de cART. Ce travail passe par la quantification in vivo d'effets de cART en utilisant des indicateurs d'activité antivirale in vitro. Nous discutons la validité des résultats et les étapes méthodologiques nécessaires pour l'intégration de ces méthodes dans les pratiques cliniques.
- 23 January 2026
- Published by Springer Nature in Bulletin of Mathematical Biology
- Vol. 88 (3) , 29
Defining Optimal Vaccine Features for Pandemic Preparedness: an Individual-Based Model Bridging Within- and Between-Host Dynamics
Disease X, a yet-to-be-identified pathogen of pandemic potential, underscores the urgency of proactive surveillance and preparedness. Developing prototype vaccine for representative pathogens is key to this effort. In alignment with the “100 Day Mission” to ensure equitable vaccine access, this study aims to identify desirable vaccine features needed to control future pathogens outbreaks, possibly SARS-CoV-2 type. We developed an individual-based transmission model integrating viral load and antibody kinetics to examine combinations of the virus’s basic reproduction number (R0) and vaccine characteristics, including (1) the concentration of antibodies required for 50% of the maximum protective effect (EC50), representing vaccine efficacy to limit infection, (2) the half-life of plasma-secreting cells associated with wanning immunity, and (3) the vaccine’s impact on the virus’s infection rate of target cells, representing vaccine’s potency to limit transmission and severity. Their impacts on infections and hospitalizations were quantified over 18 months in a population of 10,000, with vaccination starting on Day 100 under random or age-prioritized allocation, without supply constraints. Vaccines with the same features as the BNT162b2 vaccine were estimated to avert 23–47% of cases and 32–61% of hospitalizations compared to no vaccine, with effect sizes declining as R0 increased. Lowering EC50 or extending plasma-secreting cell half-life decreased transmission, although gains plateaued. Modifying the virus-target cell infection rate had minimal impact on population-level outcomes, and vaccine allocation strategy had limited impacts. Our findings suggest that vaccine development for future pandemics should prioritize improving EC50, followed by increasing a longer-term exposure.
- 23 January 2026
- Published by Springer Nature in Bulletin of Mathematical Biology
- Vol. 88 (3) , 29
Defining Optimal Vaccine Features for Pandemic Preparedness: an Individual-Based Model Bridging Within- and Between-Host Dynamics
Disease X, a yet-to-be-identified pathogen of pandemic potential, underscores the urgency of proactive surveillance and preparedness. Developing prototype vaccine for representative pathogens is key to this effort. In alignment with the “100 Day Mission” to ensure equitable vaccine access, this study aims to identify desirable vaccine features needed to control future pathogens outbreaks, possibly SARS-CoV-2 type. We developed an individual-based transmission model integrating viral load and antibody kinetics to examine combinations of the virus’s basic reproduction number (R0) and vaccine characteristics, including (1) the concentration of antibodies required for 50% of the maximum protective effect (EC50), representing vaccine efficacy to limit infection, (2) the half-life of plasma-secreting cells associated with wanning immunity, and (3) the vaccine’s impact on the virus’s infection rate of target cells, representing vaccine’s potency to limit transmission and severity. Their impacts on infections and hospitalizations were quantified over 18 months in a population of 10,000, with vaccination starting on Day 100 under random or age-prioritized allocation, without supply constraints. Vaccines with the same features as the BNT162b2 vaccine were estimated to avert 23–47% of cases and 32–61% of hospitalizations compared to no vaccine, with effect sizes declining as R0 increased. Lowering EC50 or extending plasma-secreting cell half-life decreased transmission, although gains plateaued. Modifying the virus-target cell infection rate had minimal impact on population-level outcomes, and vaccine allocation strategy had limited impacts. Our findings suggest that vaccine development for future pandemics should prioritize improving EC50, followed by increasing a longer-term exposure.
- Open Access
Joint mechanistic modeling of viral and antibody responses to vaccines in non-human primates to quantify SARS-CoV-2 mechanistic correlates of protection
In a global SARS-CoV-2 landscape of hybrid immunity resulting from a vaccinated worldwide population and the emergence of new variants able to escape immunity, the identification and quantification of correlates of protection (CoPs) is crucial for the adaptation of next-generation SARS-CoV-2 vaccines. Antibodies and their neutralizing capacity have been identified as reliable mechanistic CoPs. Here, we proposed an original mechanistic model jointly describing viral and antibody dynamics, and their mutual interactions, observed after SARS-CoV-2 infection in non-human primates (NHPs) with distinct immunological backgrounds. From the model, the concentration of neutralizing antibodies being protective against viral infection spreading was derived using the reproduction number. Counterfactual simulations were also performed to better understand and validate immune mechanisms driving immune control. The model was estimated on viral, binding (bAb), and neutralizing (nAb) antibody dynamics, with data collected in 34 naive and convalescent NHPs. Animals were involved in a preclinical study evaluating two next-generation protein-based vaccines targeting the RBD of the Spike protein to CD40-expressing cells, and the original BNT162b2 mRNA vaccine against Delta SARS-CoV-2 infection. Our model validated the functionality of nAb to neutralize viruses as the primary mechanism of protection. An inhibitory antibody concentration against Delta variant of 20 AU/mL was deemed protective against Delta infection in naive animals. Moreover, we showed the strong benefit of hybrid immunity to induce faster and more protective antibody responses pointing out the crucial role of the memory B-cell immune response in viral control. Finally, an additional effect of natural immunity beyond antibodies and enhancing the elimination of infected cells was identified, suggesting the potential role of the T-cell response in viral control. Our model showed the benefit of combining information from both viral and antibody responses to better qualitatively and quantitatively inform on their protective capacity against Delta SARS-CoV-2 infection.
Open AccessJoint mechanistic modeling of viral and antibody responses to vaccines in non-human primates to quantify SARS-CoV-2 mechanistic correlates of protection
In a global SARS-CoV-2 landscape of hybrid immunity resulting from a vaccinated worldwide population and the emergence of new variants able to escape immunity, the identification and quantification of correlates of protection (CoPs) is crucial for the adaptation of next-generation SARS-CoV-2 vaccines. Antibodies and their neutralizing capacity have been identified as reliable mechanistic CoPs. Here, we proposed an original mechanistic model jointly describing viral and antibody dynamics, and their mutual interactions, observed after SARS-CoV-2 infection in non-human primates (NHPs) with distinct immunological backgrounds. From the model, the concentration of neutralizing antibodies being protective against viral infection spreading was derived using the reproduction number. Counterfactual simulations were also performed to better understand and validate immune mechanisms driving immune control. The model was estimated on viral, binding (bAb), and neutralizing (nAb) antibody dynamics, with data collected in 34 naive and convalescent NHPs. Animals were involved in a preclinical study evaluating two next-generation protein-based vaccines targeting the RBD of the Spike protein to CD40-expressing cells, and the original BNT162b2 mRNA vaccine against Delta SARS-CoV-2 infection. Our model validated the functionality of nAb to neutralize viruses as the primary mechanism of protection. An inhibitory antibody concentration against Delta variant of 20 AU/mL was deemed protective against Delta infection in naive animals. Moreover, we showed the strong benefit of hybrid immunity to induce faster and more protective antibody responses pointing out the crucial role of the memory B-cell immune response in viral control. Finally, an additional effect of natural immunity beyond antibodies and enhancing the elimination of infected cells was identified, suggesting the potential role of the T-cell response in viral control. Our model showed the benefit of combining information from both viral and antibody responses to better qualitatively and quantitatively inform on their protective capacity against Delta SARS-CoV-2 infection.
- Open Access
A Stability-Enhanced Lasso Approach for Covariate Selection in Non-Linear Mixed Effect Model
Non-linear mixed effects models (NLMEMs) defined by ordinary differential equations (ODEs) are central to modeling complex biological systems over time, particularly in pharmacometrics, viral dynamics, and immunology. However, selecting relevant covariates associated with dynamics in high-dimensional settings remains a major challenge. This study introduces a novel model-building approach called Lasso-SAMBA (SAMBA: Stochastic Approximation for Model Building Algorithm) that integrates Lasso regression with a stability selection algorithm for robust covariate selection within ODE-based NLMEMs. The method iteratively constructs models by coupling penalized regression with mechanistic model estimation using the SAEM algorithm. It extends a prior strategy named SAMBA, originally based on stepwise inclusion, by replacing this step with a penalized, stability-driven approach that reduces false discoveries and improves selection robustness. By maintaining the monotonic decrease of the information criterion through a calibrated exploration of penalization parameters, the proposed method outperforms conventional stepwise and Bayesian variable selection alternatives. Extensive simulation studies, spanning pharmacokinetic and immunological models, demonstrate the superiority of Lasso-SAMBA in variable selection fidelity, FDR \rev{(False Discovery Proportion)} control, and computational efficiency. The Lasso-SAMBA method is implemented in an R package. Applied to a Varicella-Zoster virus vaccination study, the method reveals robust, biologically plausible associations between parameters of the mechanistic model of the humoral immune response and early transcriptomic expressions. These results underscore the practical utility of our method for high-dimensional model building in systems vaccinology and beyond.
Open AccessA Stability-Enhanced Lasso Approach for Covariate Selection in Non-Linear Mixed Effect Model
Non-linear mixed effects models (NLMEMs) defined by ordinary differential equations (ODEs) are central to modeling complex biological systems over time, particularly in pharmacometrics, viral dynamics, and immunology. However, selecting relevant covariates associated with dynamics in high-dimensional settings remains a major challenge. This study introduces a novel model-building approach called Lasso-SAMBA (SAMBA: Stochastic Approximation for Model Building Algorithm) that integrates Lasso regression with a stability selection algorithm for robust covariate selection within ODE-based NLMEMs. The method iteratively constructs models by coupling penalized regression with mechanistic model estimation using the SAEM algorithm. It extends a prior strategy named SAMBA, originally based on stepwise inclusion, by replacing this step with a penalized, stability-driven approach that reduces false discoveries and improves selection robustness. By maintaining the monotonic decrease of the information criterion through a calibrated exploration of penalization parameters, the proposed method outperforms conventional stepwise and Bayesian variable selection alternatives. Extensive simulation studies, spanning pharmacokinetic and immunological models, demonstrate the superiority of Lasso-SAMBA in variable selection fidelity, FDR \rev{(False Discovery Proportion)} control, and computational efficiency. The Lasso-SAMBA method is implemented in an R package. Applied to a Varicella-Zoster virus vaccination study, the method reveals robust, biologically plausible associations between parameters of the mechanistic model of the humoral immune response and early transcriptomic expressions. These results underscore the practical utility of our method for high-dimensional model building in systems vaccinology and beyond.
- 28 April 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 1888-1896
Comparative evaluation of methodologies for estimating the effectiveness of nonpharmaceutical interventions in the context of COVID-19: a simulation study
Numerous studies assessing the effectiveness of nonpharmaceutical interventions (NPIs) against COVID-19 have produced conflicting results, partly due to methodological differences. This study aims to clarify these discrepancies by comparing 2 frequently used approaches in terms of parameter bias and CI coverage of NPI effectiveness parameters. We compared 2-step approaches, where NPI effects are regressed on by-products of the first analysis, such as the effective reproduction number ${\mathcal{R}}_t$, with more integrated models that jointly estimate NPI effects and transmission rates in a single-step approach. We simulated datasets with mechanistic and agent-based models and analyzed them with both mechanistic models and a 2-step regression procedure. In the latter, ${\mathcal{R}}_t$ was estimated first and then used as the outcome in a linear regression with NPI variables as predictors. Mechanistic models consistently outperformed 2-step regressions, exhibiting minimal bias (0%-5%) and accurate CI coverage. Conversely, the 2-step regression showed bias up to 25%, with significantly lower-than-nominal CI coverage, reflecting challenges in uncertainty propagation. We identified additional challenges in the 2-step regression method, such high depletion of susceptibles and time lags in observational data. Our findings suggest caution when using 2-step regression methods for estimating NPI effectiveness.- 28 April 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 1888-1896
Comparative evaluation of methodologies for estimating the effectiveness of nonpharmaceutical interventions in the context of COVID-19: a simulation study
Numerous studies assessing the effectiveness of nonpharmaceutical interventions (NPIs) against COVID-19 have produced conflicting results, partly due to methodological differences. This study aims to clarify these discrepancies by comparing 2 frequently used approaches in terms of parameter bias and CI coverage of NPI effectiveness parameters. We compared 2-step approaches, where NPI effects are regressed on by-products of the first analysis, such as the effective reproduction number ${\mathcal{R}}_t$, with more integrated models that jointly estimate NPI effects and transmission rates in a single-step approach. We simulated datasets with mechanistic and agent-based models and analyzed them with both mechanistic models and a 2-step regression procedure. In the latter, ${\mathcal{R}}_t$ was estimated first and then used as the outcome in a linear regression with NPI variables as predictors. Mechanistic models consistently outperformed 2-step regressions, exhibiting minimal bias (0%-5%) and accurate CI coverage. Conversely, the 2-step regression showed bias up to 25%, with significantly lower-than-nominal CI coverage, reflecting challenges in uncertainty propagation. We identified additional challenges in the 2-step regression method, such high depletion of susceptibles and time lags in observational data. Our findings suggest caution when using 2-step regression methods for estimating NPI effectiveness.- Open Access
- 1 January 2025
- Published by Elsevier in SSRN Electronic Journal
Defining Optimal Vaccine Features for Pandemic Preparedness: An Individual-Based Model Bridging Within- and Between-Host Dynamics
Background: Disease X, a yet-to-be-identified pathogen of pandemic potential, emphasize the need for proactive surveillance and preparedness. Developing prototype vaccines for representative pathogens is crucial to achieve this goal. A “100 Day Mission” roadmap was proposed to ensure equitable vaccine access within 100 days. This study aims to identify desired vaccine features needed to control future SARS-CoV-2-like pathogens. Methods: An individual-based transmission model was developed, integrating viral load and antibody kinetics. Various combinations of the virus’s basic reproduction number (R0) and vaccine features were examined: 1) the concentration of antibodies required to achieve 50% of the vaccine's theoretical maximum protective effect (EC50), 2) plasma-secreting cell half-life, and 3) the vaccine’s impact on the virus's infection rate of target cells. Their impacts on infections and hospitalizations were quantified over 18 months in a population of 10,000. Random or age-prioritized vaccine rollout strategy began on Day 100, without supply constraints. Results: Vaccines with the same features as the currently available Bnt162b2 vaccine could avert 23-47% of cases and 32-61% of hospitalizations, compared to no vaccine. The fraction of averted cases/hospitalized decreased with increasing R0. Lowering EC50 or extending the plasma-secreting cells’ half-life reduced transmission. However, further improvements beyond an EC50 ≤3 and plasma-secreting cell half-life ≥1 year resulted in minor population-level improvements. Changes to the virus-target cell infection rate had minimal impacts on vaccine effectiveness. Vaccine effectiveness did not vary largely by allocation strategy. Conclusions: Vaccine development should focus on improving the EC50, followed by extending the half-life of plasma-secreting cells.
- 1 January 2025
- Published by Elsevier in SSRN Electronic Journal
Open AccessDefining Optimal Vaccine Features for Pandemic Preparedness: An Individual-Based Model Bridging Within- and Between-Host Dynamics
Background: Disease X, a yet-to-be-identified pathogen of pandemic potential, emphasize the need for proactive surveillance and preparedness. Developing prototype vaccines for representative pathogens is crucial to achieve this goal. A “100 Day Mission” roadmap was proposed to ensure equitable vaccine access within 100 days. This study aims to identify desired vaccine features needed to control future SARS-CoV-2-like pathogens. Methods: An individual-based transmission model was developed, integrating viral load and antibody kinetics. Various combinations of the virus’s basic reproduction number (R0) and vaccine features were examined: 1) the concentration of antibodies required to achieve 50% of the vaccine's theoretical maximum protective effect (EC50), 2) plasma-secreting cell half-life, and 3) the vaccine’s impact on the virus's infection rate of target cells. Their impacts on infections and hospitalizations were quantified over 18 months in a population of 10,000. Random or age-prioritized vaccine rollout strategy began on Day 100, without supply constraints. Results: Vaccines with the same features as the currently available Bnt162b2 vaccine could avert 23-47% of cases and 32-61% of hospitalizations, compared to no vaccine. The fraction of averted cases/hospitalized decreased with increasing R0. Lowering EC50 or extending the plasma-secreting cells’ half-life reduced transmission. However, further improvements beyond an EC50 ≤3 and plasma-secreting cell half-life ≥1 year resulted in minor population-level improvements. Changes to the virus-target cell infection rate had minimal impacts on vaccine effectiveness. Vaccine effectiveness did not vary largely by allocation strategy. Conclusions: Vaccine development should focus on improving the EC50, followed by extending the half-life of plasma-secreting cells.
- Open Access
Comparative evaluation of methodologies for estimating the effectiveness of non-pharmaceutical interventions in the context of COVID-19: a simulation study
Numerous studies assessing the effectiveness of non-pharmaceutical interventions (NPIs) against COVID-19 have produced conflicting results, partly due to methodological differences. This study aims to clarify these discrepancies by comparing two frequently used approaches in terms of parameter bias and confidence interval coverage of NPI effectiveness parameters. We compared two-step approaches, where NPI effects are regressed on by-products of a first analysis, such as the effective reproduction number ℛ t , with more integrated models that jointly estimate NPI effects and transmission rates in a single-step approach. We simulated datasets with mechanistic and an agent-based models and analyzed them with both mechanistic models and a two-step regression procedure. In the latter, ℛ t was estimated first and then used as the outcome in a linear regression with NPI variables as predictors. Mechanistic models consistently outperformed two-step regressions, exhibiting minimal bias (0-5%) and accurate confidence interval coverage. Conversely, the two-step regression showed up to 25% bias, with significantly lower-than-nominal confidence interval coverage, reflecting challenges in uncertainty propagation. We identified additional challenges in the two-step regression method, such high depletion of susceptibles and time lags in observational data. Our findings suggest caution when using two-step regression methods for estimating NPI effectiveness.
Open AccessComparative evaluation of methodologies for estimating the effectiveness of non-pharmaceutical interventions in the context of COVID-19: a simulation study
Numerous studies assessing the effectiveness of non-pharmaceutical interventions (NPIs) against COVID-19 have produced conflicting results, partly due to methodological differences. This study aims to clarify these discrepancies by comparing two frequently used approaches in terms of parameter bias and confidence interval coverage of NPI effectiveness parameters. We compared two-step approaches, where NPI effects are regressed on by-products of a first analysis, such as the effective reproduction number ℛ t , with more integrated models that jointly estimate NPI effects and transmission rates in a single-step approach. We simulated datasets with mechanistic and an agent-based models and analyzed them with both mechanistic models and a two-step regression procedure. In the latter, ℛ t was estimated first and then used as the outcome in a linear regression with NPI variables as predictors. Mechanistic models consistently outperformed two-step regressions, exhibiting minimal bias (0-5%) and accurate confidence interval coverage. Conversely, the two-step regression showed up to 25% bias, with significantly lower-than-nominal confidence interval coverage, reflecting challenges in uncertainty propagation. We identified additional challenges in the two-step regression method, such high depletion of susceptibles and time lags in observational data. Our findings suggest caution when using two-step regression methods for estimating NPI effectiveness.
- 31 May 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (6) , 1447-1457
Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption
Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint is commonly used as endpoint to evaluate their efficacy. However, in line with recommendations from a consensus meeting, to minimize the risk of increased viremia without ART, trials often implement short ATI phases and stringent virological ART restart criteria. This approach can limit the accurate observation of the setpoint. Methods: We analyzed viral dynamics in 235 people with HIV from 3 trials, examining virological criteria during ATI phases. Time-related (eg time to rebound, peak, and setpoint) and viral load magnitude–related criteria (peak, setpoint, and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify (1) surrogate endpoints for setpoint and (2) optimal virological ART restart criteria mitigating the risks of ART interruption and the evaluation of viral control. Results: Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC the most strongly correlated with the setpoint, with correlations >0.70. A threshold >100 000 copies/mL for 2 consecutive measures is requested as a virological ART restart criterion. Conclusions: Our results are in line with recommendations and emphasize the benefits of an ATI phase >12 weeks, with regular monitoring, and a virological ART restart criterion of 10 000 copies/mL to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy to the setpoint.
- 31 May 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (6) , 1447-1457
Definition of Virological Endpoints Improving the Design of HIV Cure Strategies Using Analytical Antiretroviral Treatment Interruption
Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint is commonly used as endpoint to evaluate their efficacy. However, in line with recommendations from a consensus meeting, to minimize the risk of increased viremia without ART, trials often implement short ATI phases and stringent virological ART restart criteria. This approach can limit the accurate observation of the setpoint. Methods: We analyzed viral dynamics in 235 people with HIV from 3 trials, examining virological criteria during ATI phases. Time-related (eg time to rebound, peak, and setpoint) and viral load magnitude–related criteria (peak, setpoint, and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify (1) surrogate endpoints for setpoint and (2) optimal virological ART restart criteria mitigating the risks of ART interruption and the evaluation of viral control. Results: Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC the most strongly correlated with the setpoint, with correlations >0.70. A threshold >100 000 copies/mL for 2 consecutive measures is requested as a virological ART restart criterion. Conclusions: Our results are in line with recommendations and emphasize the benefits of an ATI phase >12 weeks, with regular monitoring, and a virological ART restart criterion of 10 000 copies/mL to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy to the setpoint.
- Open Access
Definition of viroIogical endpoints improving the design of HIV cure strategies using analytical antiretroviral treatment interruption
Background Analytical treatment interruption (ATI) is the gold standard in HIV research to validate the ability of novel therapeutic strategies to long-term control viremia without antiretroviral treatment (ART). Viral setpoint is commonly used as endpoint to evaluate their efficacy. However, to mitigate higher viremia risk without ART, trials use short ATI phases and strict virological ART re-start criteria, compromising the observation of the setpoint. Methods We analyzed viral dynamics in 235 HIV-infected participants from three trials, examining various virological criteria during ATI phases. Time-related (e.g. time to rebound, peak and setpoint) and VL magnitude-related criteria (peak, setpoint and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify surrogate endpoints for setpoints. Additional correlation analyzes were performed to identify optimal virological ART re-start criteria mitigating the risks of ART interruption and the evaluation of viral control. Results Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC identified as the criterion most strongly correlated with the setpoint, with correlations higher than 0.70. A threshold of at least 100,000 copies/mL for two consecutive VL measurements is requested as virological ART re-start criteria to keep strong correlations between the setpoint and nAUC. Conclusions Our results emphasize the benefits of an ATI phase longer than 12 weeks, with regular monitoring, and a VL threshold of 100,000 copies/mL as virological ART re-start criteria to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy for the setpoint.
Open AccessDefinition of viroIogical endpoints improving the design of HIV cure strategies using analytical antiretroviral treatment interruption
Background Analytical treatment interruption (ATI) is the gold standard in HIV research to validate the ability of novel therapeutic strategies to long-term control viremia without antiretroviral treatment (ART). Viral setpoint is commonly used as endpoint to evaluate their efficacy. However, to mitigate higher viremia risk without ART, trials use short ATI phases and strict virological ART re-start criteria, compromising the observation of the setpoint. Methods We analyzed viral dynamics in 235 HIV-infected participants from three trials, examining various virological criteria during ATI phases. Time-related (e.g. time to rebound, peak and setpoint) and VL magnitude-related criteria (peak, setpoint and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify surrogate endpoints for setpoints. Additional correlation analyzes were performed to identify optimal virological ART re-start criteria mitigating the risks of ART interruption and the evaluation of viral control. Results Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC identified as the criterion most strongly correlated with the setpoint, with correlations higher than 0.70. A threshold of at least 100,000 copies/mL for two consecutive VL measurements is requested as virological ART re-start criteria to keep strong correlations between the setpoint and nAUC. Conclusions Our results emphasize the benefits of an ATI phase longer than 12 weeks, with regular monitoring, and a VL threshold of 100,000 copies/mL as virological ART re-start criteria to limit the risk for patients while capturing enough information to keep nAUC as an optimal proxy for the setpoint.
- Open Access
- 8 November 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-16
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody concentrations were analyzed from 487 participants enrolled in six Phase I and Phase II clinical trials conducted by the EBOVAC1 and EBOVAC2 consortia. A model based on ordinary differential equations describing the dynamics of antibodies and short- and long-lived antibody-secreting cells (ASCs) was used to model the humoral response from 7 days after the second vaccination to a follow-up period of 2 years. Using a population-based approach, we first assessed the robustness of the model, which was originally estimated based on Phase I data, against all data. Then we assessed the longevity of the humoral response and identified factors that influence these dynamics. We estimated a half-life of the long-lived ASC of at least 15 years and found an influence of geographic region, sex, and age on the humoral response dynamics, with longer antibody persistence in Europeans and women and higher production of antibodies in younger participants.
- 8 November 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-16
Open AccessPrediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody concentrations were analyzed from 487 participants enrolled in six Phase I and Phase II clinical trials conducted by the EBOVAC1 and EBOVAC2 consortia. A model based on ordinary differential equations describing the dynamics of antibodies and short- and long-lived antibody-secreting cells (ASCs) was used to model the humoral response from 7 days after the second vaccination to a follow-up period of 2 years. Using a population-based approach, we first assessed the robustness of the model, which was originally estimated based on Phase I data, against all data. Then we assessed the longevity of the humoral response and identified factors that influence these dynamics. We estimated a half-life of the long-lived ASC of at least 15 years and found an influence of geographic region, sex, and age on the humoral response dynamics, with longer antibody persistence in Europeans and women and higher production of antibodies in younger participants.